Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
Choi UY, Kim KH, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Song SE, Jo DS, Lee J, Ma SH, Kim KN, Kang JH. Choi UY, et al. Among authors: kim cs, kim kn, kim dh, kim hm, kim kh, kim jh. Vaccine. 2021 Apr 8;39(15):2103-2109. doi: 10.1016/j.vaccine.2021.03.005. Epub 2021 Mar 16. Vaccine. 2021. PMID: 33736920 Clinical Trial.
Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial.
Han SB, Rhim JW, Shin HJ, Lee SY, Kim HH, Kim JH, Lee KY, Ma SH, Park JS, Kim HM, Kim CS, Kim DH, Choi YY, Cha SH, Hong YJ, Kang JH. Han SB, et al. Among authors: kim hh, kim cs, kim dh, kim hm, kim jh. Hum Vaccin Immunother. 2015;11(5):1094-102. doi: 10.1080/21645515.2015.1017693. Hum Vaccin Immunother. 2015. PMID: 25875868 Free PMC article. Clinical Trial.
Immunogenicity and safety of the new reduced-dose tetanus-diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study.
Han SB, Rhim JW, Shin HJ, Kim SY, Kim JH, Kim HH, Lee KY, Kim HM, Choi YY, Ma SH, Kim CS, Kim DH, Ahn DH, Kang JH. Han SB, et al. Among authors: kim hh, kim cs, kim dh, kim hm, kim sy, kim jh. J Microbiol Immunol Infect. 2017 Apr;50(2):207-213. doi: 10.1016/j.jmii.2015.04.005. Epub 2015 May 14. J Microbiol Immunol Infect. 2017. PMID: 26055693 Free article. Clinical Trial.
Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea.
Kim YK, Vidor E, Kim HM, Shin SM, Lee KY, Cha SH, Ma SH, Kim DH, Lee J, Park SE, Lee H, Kim JD, Kim KH, Kim KH, Kim JH; A3L31 Study Group. Kim YK, et al. Among authors: kim dh, kim hm, kim jd, kim kh, kim jh. Vaccine. 2017 Jul 13;35(32):4022-4028. doi: 10.1016/j.vaccine.2017.05.062. Epub 2017 Jun 16. Vaccine. 2017. PMID: 28629923 Clinical Trial. No abstract available.
Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study.
Kim KH, Kim CS, Kim HM, Kim JD, Ma SH, Kim DH, Hwang PH, Han JW, Lee TJ, Kim JH, Karkada N, Mesaros N, Sohn WY, Kim JH. Kim KH, et al. Among authors: kim cs, kim dh, kim hm, kim jd, kim jh. Hum Vaccin Immunother. 2019;15(2):317-326. doi: 10.1080/21645515.2018.1536588. Epub 2018 Nov 15. Hum Vaccin Immunother. 2019. PMID: 30431387 Free PMC article. Clinical Trial.
Recommended immunization schedule for children and adolescents: the Korean Pediatric Society, 2013.
Jo DS, Kim JH, Choi EH, Park SE, Kim YJ, Kim YK, Lee J, Eun BW, Lee SY, Lee H, Kim KH, Kim KH; Korean Pediatric Society, Committee on Infectious Diseases. Jo DS, et al. Among authors: kim yj, kim yk, kim kh, kim jh. Korean J Pediatr. 2013 Jun;56(6):231-4. doi: 10.3345/kjp.2013.56.6.231. Epub 2013 Jun 21. Korean J Pediatr. 2013. PMID: 23807888 Free PMC article.
32,371 results
You have reached the last available page of results. Please see the User Guide for more information.